Literature summary for 3.5.1.23 extracted from

Tan, S.F.; Dunton, W.; Liu, X.; Fox, T.E.; Morad, S.A.F.; Desai, D.; Doi, K.; Conaway, M.R.; Amin, S.; Claxton, D.F.; Wang, H.G.; Kester, M.; Cabot, M.C.; Feith, D.J.; Loughran, T.P.
Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-kappaB-dependent P-glycoprotein upregulation (2019), J. Lipid Res., 60, 1078-1086 .

Search for more literature for 3.5.1.23

Cloned(Commentary)

Cloned (Comment)	Organism
gene ASAH1, recombinant overexpression in HEK-293T/17 cells, quantitative real-time RT-PCR enzyme expression analysis	Homo sapiens

Protein Variants

Protein Variants	Comment	Organism
additional information	overexpression and knockdown of acid ceramidase via lentiviral transduction in HEK-293T/17 cells	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	Q13510	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
myeloid leukemia cell	-	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
acid ceramidase	-	Homo sapiens
ASAH1	-	Homo sapiens

General Information

General Information	Comment	Organism
malfunction	acid ceramidase overexpression in HL-60 confers resistance to the acute myeloid leukemia chemotherapeutic drugs, cytarabine, mitoxantrone, and daunorubicin, and is linked to P-glycoprotein upregulation	Homo sapiens
metabolism	acid ceramidase overexpression increased NF-kappaB activation whereas NF-kappaB inhibitors reduce P-glycoprotein levels, indicating that the NF-kappaB pathway contributes to acid ceramidase-mediated modulation of P-glycoprotein expression	Homo sapiens
physiological function	acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-kappaB-dependent P-glycoprotein upregulation. Elevated acid ceramidase levels in acute myeloid leukemia contribute to blast survival. Important role for the enzyme in drug resistance as well as cell survival	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)